The long term goal of our laboratory is to identify novel therapeutic targets for triple-negative breast cancer (TNBC), which lacks estrogen receptor, progesterone receptor, and HER2. To reach this goal, we are studying: 1) molecular determinants of TNBC therapy resistance, and 2) contributions of adipose stem cells to TNBC initiation/ progression.
Education and Training
- Instructor in Medicine, Medicine, Harvard University , 1997 - 2005
- Research Fellow, Pediatric Oncology, Harvard University , 1996 - 1997
- Research Fellow, Medicine, Harvard University , 1995 - 1996
- Ph.D., Harvard University , 1995
- Collection of Surplus Tissue from Reduction Mammoplasty - Pro00107672
- Assessing Adipose Senescence As a Predictor of Graft Survival and Volume Retention
- Evaluating the presence of bacterial bio-burden on surgical drains and the efficacy of UV light therapy for drain disinfection.
- Development of an Optimized Human Antibody to a Novel Target for the Treatment of Fibrotic Diseases
- Targeting precursor neural (N)-cadherin to eliminate chemotherapy-resistant triple-negative breast tumor cells
- Targeting precursor N-cadherin to eliminate docetaxel-resistant, castration-resistant prostate cancer using an animal model
- Targeting nuclear FGF receptor to improve chemotherapy response in triple-negative breast cancer
- Nuclear Snail-1 in the progression of Estrogen Receptor(-) invasive breast cancer
- Novel Function for VEGF in Breast Carcinoma Survival